Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Changes in the serotype distribution of Streptococcus pneumoniae causing otitis media after PCV13 introduction in Spain.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
      Pneumococcal Vaccines*; Otitis Media/*epidemiology ; Otitis Media/*prevention & control ; Pneumococcal Infections/*epidemiology ; Pneumococcal Infections/*prevention & control ; Streptococcus pneumoniae/*immunology; Adolescent ; Child ; Child, Preschool ; Coinfection/epidemiology ; Coinfection/microbiology ; Coinfection/prevention & control ; Ear, Middle/immunology ; Ear, Middle/microbiology ; Humans ; Infant ; Infant, Newborn ; Otitis Media/etiology ; Otitis Media/microbiology ; Pneumococcal Infections/microbiology ; Prospective Studies ; Serotyping ; Spain/epidemiology ; Streptococcus pneumoniae/isolation & purification ; Time Factors ; Vaccines, Conjugate
    • نبذة مختصرة :
      One of the beneficial effects of pneumococcal conjugate vaccines (PCVs) has been a decrease in the incidence of non-invasive infections, such as otitis media (OM) caused by vaccine serotypes. In this study, we analyzed the epidemiology of pneumococcal OM before and after PCV13 introduction in 2010. Between 2008 and 2016, the middle ear exudates from 2653 children under 14 years of age with OM were studied in two Spanish provinces (Gipuzkoa and Barcelona), and S. pneumoniae was isolated in 235 (8.9%) of cases. The 204 available isolates were serotyped and distributed in three 3-year periods: one before and two after PCV13 introduction (early and late post-PCV13). A significant decrease in the rate of OM caused by S. pneumoniae was observed mainly due to a decrease in infections caused by all PCV13 serotypes, although exceptions were observed including the persistence of serotype 3 in Gipuzkoa and a weak re-emergence of serotype 19F in both regions. The rate and diversity of non-PCV13 serotypes increased in both regions and an emerging clone causing OM was detected in each region: serotype 23B ST2372 in Gipuzkoa and serotype 11A ST838/ST6521 in Barcelona. The introduction of PCV13 has been followed by a change in the epidemiology of pneumococcal OM, with a decrease in the rate of vaccine serotypes accompanied by an increase in the diversity of non-vaccine serotype and the clonal spreading of different single clones in each region.
      Competing Interests: JMM has been a member of an Advisory Board for PCV13 for Pfizer. CMA has been a member of an Advisory Board for GSK and received a travel grant from Pfizer. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
    • References:
      Lancet Infect Dis. 2015 May;15(5):535-43. (PMID: 25801458)
      PLoS One. 2012;7(4):e36226. (PMID: 22558393)
      PLoS One. 2017 Feb 1;12(2):e0170316. (PMID: 28146590)
      J Clin Microbiol. 2016 Aug;54(8):2197-200. (PMID: 27280423)
      PLoS One. 2015 Sep 14;10(9):e0137565. (PMID: 26368279)
      Clin Infect Dis. 2005 Jun 15;40(12):1738-44. (PMID: 15909260)
      Eur J Pediatr. 2015 Mar;174(3):355-64. (PMID: 25169065)
      PLoS One. 2017 Aug 14;12(8):e0183191. (PMID: 28806737)
      Lancet Infect Dis. 2015 Mar;15(3):301-9. (PMID: 25656600)
      Pediatr Infect Dis J. 2006 Jul;25(7):602-7. (PMID: 16804429)
      Lancet. 2004 Feb 7;363(9407):465-73. (PMID: 14962529)
      BMC Infect Dis. 2015 May 05;15:207. (PMID: 25940580)
      Clin Infect Dis. 2014 Dec 15;59(12):1724-32. (PMID: 25159581)
      Emerg Infect Dis. 2014 Feb;20(2):201-10. (PMID: 24447437)
      Genome Biol Evol. 2017 Aug 1;9(8):2122-2135. (PMID: 28910966)
      Pediatrics. 2013 Mar;131(3):e964-99. (PMID: 23439909)
      PLoS One. 2013;8(1):e54333. (PMID: 23349853)
      Lancet Infect Dis. 2014 Mar;14(3):205-12. (PMID: 24287186)
      BMC Infect Dis. 2012 Mar 22;12:69. (PMID: 22440017)
      Pediatr Infect Dis J. 2017 Mar;36(3):274-281. (PMID: 27918383)
      Pediatr Infect Dis J. 2014 Nov;33(11):e286-90. (PMID: 24911895)
      Lancet Infect Dis. 2016 Apr;16(4):480-92. (PMID: 27036355)
      Clin Infect Dis. 2000 Jan;30(1):100-21. (PMID: 10619740)
      Clin Microbiol Infect. 2015 Jan;21(1):35-42. (PMID: 25636925)
      Lancet Infect Dis. 2014 Sep;14(9):839-46. (PMID: 25042756)
      PLoS One. 2012;7(8):e43619. (PMID: 22928005)
      PLoS One. 2016 Mar 08;11(3):e0151125. (PMID: 26953887)
      Clin Infect Dis. 2015 May 1;60(9):1339-45. (PMID: 25648240)
      PLoS Pathog. 2007 Nov;3(11):e168. (PMID: 18020702)
      Infect Immun. 2004 Jan;72(1):76-81. (PMID: 14688083)
      BMJ. 1997 Jul 12;315(7100):98-102. (PMID: 9240050)
    • الرقم المعرف:
      0 (Pneumococcal Vaccines)
      0 (Vaccines, Conjugate)
    • الموضوع:
      Date Created: 20181219 Date Completed: 20190521 Latest Revision: 20240406
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC6298674
    • الرقم المعرف:
      10.1371/journal.pone.0209048
    • الرقم المعرف:
      30562385